Table 1.

Clinical and socio-demographic features of CML patients and controls.

Sample	Gender	Race	Age	Diagnosis	Treatment	Response
							1	F	Yellow	63	CML Chronic Phase	At diagnosis
2	M	White	61	CML Chronic Phase	At diagnosis
3	M	White	57	CML Chronic Phase	At diagnosis
4	F	White	31	CML Chronic Phase	At diagnosis
5	M	Black	40	CML Chronic Phase	At diagnosis
6	F	White	68	CML Chronic Phase	At diagnosis
7	F	White	74	CML Chronic Phase	At diagnosis
8	M	White	52	CML Chronic Phase	At diagnosis
9	M	White	38	CML Chronic Phase	At diagnosis
10	M	White	20	CML Chronic Phase	At diagnosis
11	M	White	29	CML Chronic Phase	Imatinib	CCyR/CMR
12	M	White	56	CML Chronic Phase	Dasatinib	CCyR/CMR
13	M	White	45	CML Chronic Phase	Dasatinib	CCyR/CMR
14	M	White	56	CML Chronic Phase	Imatinib	CCyR/CMR
15	F	White	47	CML Chronic Phase	Imatinib	MR 5.0
16	F	White	60	CML Chronic Phase	Dasatinib	MR 5.1
17	F	White	41	CML Advanced Phase	Dasatinib	Resistant
18	M	White	32	CML Advanced Phase	Dasatinib	Resistant
19	M	White	53	CML Advanced Phase	Nilotinib	Resistant
20	F	White	69	CML Advanced Phase	Dasatinib	Resistant
21	M	White	34	CML Advanced Phase	Dasatinib	Resistant
22	F	White	64	CML Advanced Phase	Nilotinib	Resistant
23	M	Black	28	CML Advanced Phase	Dasatinib	CCyR/CMR
24	M	White	33	CML Advanced Phase	Dasatinib	CMR
25	M	White	63	CML Advanced Phase	Dasatinib	CCyR/CMR
26	F	White	62	CML Advanced Phase	Imatinib	Resistant
27	F	Black	63	CML Advanced Phase	Nilotinib	Resistant
28	F	White	76	CML Advanced Phase	Dasatinib	Resistant
29	M	Black	29	CML Advanced Phase	At diagnosis
30	F	White	41	Control
31	M	White	54	Control
32	M	White	23	Control
33	F	Black	47	Control
34	M	White	42	Control
35	M	White	51	Control
36	M	White	68	Control
37	M	White	50	Control
38	F	Black	54	Control
39	F	White	34	Control

F, female; M, male; CCyR, Complete cytogenetic response; CMR, complete molecular response; MR, molecular response.